Basel, 14 December 2005
Changes
on Corporate
Executive Committee and Board of Directors of Roche
Heino von Prondzynski,
CEO Division Roche Diagnostics, has decided to retire from his executive functions in the course of
next year in order to pursue personal interests. At its last meeting, the Board of Directors of Roche
has appointed Severin Schwan as the new CEO Division Roche Diagnostics and as a member of the Corporate
Executive Committee, effective 1 January, 2006. Severin Schwan is currently regional head Asia-Pacific
of Roche Diagnostics.
Also, per 1 January, 2006, Burkhard G. Piper is
appointed as a member of the Enlarged Corporate Executive Committee. Burkhard G. Piper was recently
appointed head of the diagnostics business unit Roche Diabetes Care following the retirement of Staffan
Ek.
As of 1 January, 2006, the Corporate Executive Committee (CEC) of
Roche will have the following composition:
Corporate Executive Committee: | |
| Franz B. Humer (1946) | Chairman and CEO of the Roche Group |
| Erich
Hunziker (1953) | Chief Financial Officer, Deputy Head of the Corporate Executive Committee |
| William
Burns (1947) | CEO Division Roche Pharma |
| Severin Schwan (1967) | CEO Division
Roche Diagnostics |
| Jonathan Knowles (1947) | Head Global Research |
| Gottlieb
Keller (1954) | Head Corporate Services and Human Resources |
| | |
| Enlarged
Corporate Executive Committee: | |
| Ed Holdener (1945) | Head Global Pharma Development |
| Peter
Hug (1958) | Head Pharma Partnering |
| Burkhard G. Piper (1961) | Head Business Unit Roche
Diabetes Care |
| Rolf Schläpfer (1956) | Head Corporate Communications |
| Osamu
Nagayama (1947) | President and CEO Chugai |
| | |
| Secretary to the Corporate Executive
Committee: | |
| Pierre Jaccoud (1955) | Head Chairman’s Office |
Franz
B. Humer, Chairman and CEO von Roche: „For many years, Heino von Prondzynski has significantly contributed
to the outstanding success of our Diagnostics division. Under his leadership the Division has substantially
strengthened its global No 1 position and we express our deep gratitude to him for his distinguished
service. With the appointment of Severin Schwan and Burkhard G. Piper we continue to rejuvenate
our senior leadership team with highly qualified Roche managers.“
Changes
on Board of Directors At the Annual General Meeting (AGM) on 27 February, 2006
the regular
terms of Rolf Hänggi, Peter Brabeck-Letmathe, DeAnne Julius and Prof. Horst Teltschik will end. The
Board of Directors proposes to the AGM the re-election of Peter Brabeck-Letmathe, DeAnne Julius and
Prof. Horst Teltschik as members of the Board of Directors of Roche for another term of four years.
Rolf Hänggi who served the Board of Directors as its Vice President
since 1996 has announced his intention not to stand for re-election. The Board of Directors proposes
to the AGM the election of Prof. Beatrice Weder di Mauro as a new Board member.
Curricula
vitae Swiss national Beatrice Weder di Mauro was born 1965 in Basel. Since 2001
she is
a professor of economics at the University of Mainz and since August 2004, she is a member of the German
Council of Economic Experts. Previously she worked as an economist at the International Monetary Fund
and at the World Bank, Washington. She holds a PhD from the University of Basel.
The
Austrian Severin Schwan, born 1967, graduated in economics and also holds a doctorate in law. His career
with Roche began in 1993 at the Corporate Finance department in Basle. After various international positions
Severin Schwan became Head of Global Finance & Services for Roche Diagnostics, before he took over
as Head of Region Asia Pacific for the Diagnostics division.
Burkhard
G. Piper, a German by nationality, was born 1961 and has a Diploma in industrial economics. He started
his business career in 1985 with Boehringer Mannheim, a healthcare company which was later acquired
by Roche. After several management positions in marketing he was appointed General Manager of Roche
Diagnostics Canada in 1999. In 2002 Burkhard Piper took over the position as Head Centralized Diagnostics
and since 2005 he leads the Business Unit Roche Diabetes Care.
About
Roche Headquartered in Basel, Switzerland, Roche is one of the world’s leading
research-focused
healthcare groups in the fields of pharmaceuticals and diagnostics. As a supplier of innovative products
and services for the early detection, prevention, diagnosis and treatment of disease, the Group contributes
on a broad range of fronts to improving people’s health and quality of life. Roche is a world leader
in diagnostics, the leading supplier of medicines for cancer and transplantation and a market leader
in virology. Roche employs roughly 65,000 people in 150 countries and has R&D agreements and strategic
alliances with numerous partners, including majority ownership interests in Genentech and Chugai. Additional
information about the Roche Group is available on the Internet (www.roche.com). |
 |